Targeted therapy for colorectal cancer after first chemotherapy
Part of Cancer clinical trials.
This trial tests a new targeted therapy (SHR-1811) for colorectal cancer that has grown despite initial chemotherapy. It may help people whose tumors have certain HER2 protein levels, offering a treatment option after standard therapy has stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have colorectal cancer that has spread or returned and cannot be surgically removed.
- Your cancer progressed after your first round of chemotherapy (with oxaliplatin and a fluoropyrimidine).
- Your tumor tests positive for HER2 (either high or low levels).
- You are able to care for yourself (ECOG score 0-1) and have adequate organ function, including blood counts and liver/kidney function.
- You have not had active brain metastases, and you have not previously taken an HER2-targeted antibody-drug conjugate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of oral chemotherapy, targeted therapy, and immunotherapy, with or without radiation, for people with advanced colorectal cancer that hasn't responded to at least two prior treatments. The goal is to see if this approach can help shrink tumors or slow the disease.
This trial tests a new targeted drug (SHR-A1811) combined with chemotherapy and bevacizumab versus the usual therapy for advanced colorectal cancer that hasn't been treated yet. It aims to see if the new combo works better as a first treatment.
This study tests a new combination of three drugs for advanced colorectal cancer that has not responded to standard treatments. The goal is to see if this combination can shrink tumors or slow down the cancer's growth.
This trial tests a combination of three new drugs (SHR-1701, SHR2554, and BP102) for people with metastatic colorectal cancer. The goal is to see if these drugs can shrink tumors or slow the cancer's growth.
This trial tests a new drug (TQB2930) combined with chemotherapy, with or without another drug called bevacizumab, for people whose colorectal cancer has spread or cannot be removed by surgery and has a specific protein called HER2. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This study tests a combination of two drugs (bevacizumab and adebrelimab) for people with a specific type of advanced colorectal cancer that has not responded to standard treatments. It aims to see if this combination can help control the cancer and improve outcomes.
Hear when a new mCRC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.